Last reviewed · How we verify
NCT03161925: CLCS
Chinese Liver Cancer Clinical Survey
trial in Primary Liver Cancer in 5,000 participants. Status unknown.
31 August 2017
Quick facts
| Lead sponsor | Beijing Insight Science & Technology Co. Ltd. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 28 November 2016 |
| Primary completion | 31 August 2017 |
| Estimated completion | 31 August 2017 |
Conditions studied
- Primary Liver Cancer — all drugs for Primary Liver Cancer →
Sponsor
Beijing Insight Science & Technology Co. Ltd.
Who can join
Eligibility, any sex, with Primary Liver Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In order to make better use of clinical resources of the real world, strengthen the standardization of PLC diagnosis and treatment, and constantly improve the academic level of liver cancer in China, we intends to launch "Chinese Liver Cancer clinical Survey" project in cancer specialized hospitals and large general hospitals and to explore the best clinical pathway of PLC multidisciplinary consultation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03161925
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Primary Liver Cancer
Currently open trials in the same condition.
- NCT07437859 — Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironme · active not recruiting
- NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
- NCT07466602 — cfDNA Methylation for Liver Cancer Recurrence Detection · recruiting
- NCT06914648 — The Dragon PLC Trial (DRAGON-PLC) · NA · recruiting
- NCT06905015 — Stroke Volume Variation Versus Central Venous Pressure Guidance for Reducing Perioperative Blood Loss During Open Liver · NA · recruiting
Other Beijing Insight Science & Technology Co. Ltd. trials
Trials by the same sponsor.
- NCT03178929 — Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03161925 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Insight Science & Technology Co. Ltd.
- Last refreshed: 22 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03161925.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing